85岁以上转移性去势抵抗性前列腺癌患者队列中PSMA放射配体治疗的疗效与安全性
该回顾性分析纳入21例85岁及以上转移性去势抵抗性前列腺癌(mCRPC)患者,接受[177Lu]Lu-PSMA-617放射配体治疗(中位4个周期,平均累积给药活度26.9±17.3 GBq)。全队列平均最佳PSA反应为-37.6±73.3%,62%(13/21)达部分缓解;中位无进展生存期4.6个月,总生存期14.7个月;严重不良事件仅2例。
要点
- 85岁及以上mCRPC患者接受PSMA放射配体治疗,平均最佳PSA反应为-37.6±73.3%,62%达部分缓解。
- 中位无进展生存期4.6个月,中位总生存期14.7个月。
- 严重不良事件罕见,仅2例:1例3级贫血和1例3级血小板减少。
核心结论
- PSMA放射配体治疗对85岁以上mCRPC患者有效且耐受性良好,临床结局与安全性可与年轻人群研究中所观察到的结果相比。
- 这凸显其作为该老龄患者群体有价值治疗选择的潜力。
研究设计与样本
- 回顾性分析纳入21例85岁及以上(范围85-96岁)接受PSMA放射配体治疗的mCRPC患者。
- 中位治疗周期数为4个(范围1-13个周期),[177Lu]Lu-PSMA-617平均累积给药活度为26.9±17.3 GBq(范围8.0-87.2 GBq)。
- 不良事件包括贫血、血小板减少、白细胞减少、肾功能损害、疲乏和口干,按CTCAE 5.0版分级。
主要发现
- 全队列平均最佳PSA反应为-37.6±73.3%,62%(13/21例)显示部分缓解。
- 中位无进展生存期为4.6个月,中位总生存期为14.7个月。
- 严重不良事件罕见,发生于2例患者:1例3级贫血和1例3级血小板减少。
关键数值与推荐
- 全队列平均最佳PSA反应为-37.6±73.3%,62%(13/21例)达部分缓解。
- 中位无进展生存期4.6个月,中位总生存期14.7个月。
- 严重不良事件2例:1例3级贫血、1例3级血小板减少。
临床怎么用
- 原文结论指出PSMA放射配体治疗对85岁以上mCRPC患者有效且耐受性良好,临床结局与安全性可与年轻人群研究相比,凸显其作为该老龄患者群体有价值治疗选择的潜力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: With increasing life expectancy, the number of older patients with metastatic castration-resistant prostate cancer (mCRPC) continues to rise, but this group is currently underrepresented in clinical trials. This study aims to assess the efficacy and safety of prostate-specific membrane antigen (PSMA) targeted radioligand therapy (RLT) in patients over 85 years old with mCRPC. MATERIALS AND METHODS: A retrospective analysis was conducted on 21 mCRPC patients aged 85 years or older receiving PSMA-RLT (range: 85-96 y). The median number of treatment cycles was 4 (range: 1-13 cycles), with a mean cumulative administered activity of 26.9±17.3 GBq (range: 8.0-87.2 GBq) of [ 177 Lu]Lu-PSMA-617. Adverse events, including anemia, thrombocytopenia, leukopenia, renal impairment, fatigue, and xerostomia were classified according to CTCAE version 5.0. RESULTS: The mean best PSA response across the cohort was -37.6±73.3%, with 62% (13 of 21 patients) showing partial remission. Median progression-free survival and overall survival were 4.6 and 14.7 months, respectively. Severe adverse events were rare, occurring in 2 patients: 1 case of grade 3 anemia and 1 of grade 3 thrombocytopenia. CONCLUSIONS: The results demonstrate that PSMA-RLT is an effective and well-tolerated treatment for mCRPC patients over 85 years, with clinical outcomes and safety comparable to those observed in studies involving younger populations. This highlights its potential as a valuable therapeutic option for this aging patient group.
引用
- Bastian MB, Wörl B, Blickle A, et al. PSMA Radioligand Therapy in Advanced Age: Insights From an 85y+ mCRPC Patient Cohort. Clin Nucl Med. 2025. PMID: 40358397. doi:10.1097/RLU.0000000000005968
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。